No abstract

No abstract

Cytomegalovirus (CMV) infection/reactivation is a serious complication after hematopoietic cell transplantation (HCT). The DNA vaccine ASP0113 contains two plasmids encoding CMV antigens (glycoprotein B and tegument phosphoprotein 65) that stimulate humoral and cellular immunity. Between June 2013 and February 2014, Astellas conducted a phase 2, open-label, uncontrolled, three-center trial to investigate the safety and tolerability of ASP0113 in Japanese patients undergoing HCT for hematologic disorders. Ten patients aged 22-61 years were enrolled; nine received at least one dose of ASP0113. Six patients received all five doses of ASP0113 5 mg at intervals before and after HCT. Pre-emptive antiviral therapy was allowed. One patient died following relapse of primary disease. All patients had serious adverse events deemed unrelated to ASP0113. CMV viremia (assessed by CMV antigenemia) occurred in seven patients, who then received anti-CMV therapy. No patients developed CMV end-organ disease. Adverse events associated with ASP0113 injection included pyrexia (three patients), skin reactions [injection site pain, injection site tenderness, and erythema (two patients each); and rash, injection site erythema, injection site induration, and injection site swelling (one patient each)], and hyperuricemia (one patient). ASP0113 was well tolerated in Japanese HCT recipients. Further studies should evaluate its efficacy and safety. ClinicalTrials.gov Identifier: NCT01903928.

Fe-Pd binary alloy films with various alloy compositions (from 7.8 at% Pd to 77.1 at% Pd) were electrodeposited in a novel bath containing the ammonia solution and the ammonium tartrate as complexing agents by changing the bath composition and the current density. The chemical states of the deposited films were analyzed by using ESCA, and the crystallographic structures of deposited films with wide alloy compositions were determined by using XRD and HRTEM. The result indicated that the crystallographic structures of deposited films are theFe solid solution when the Pd content is below 14.3 at% Pd, the mixture of -Fe solid solution and (-Fe, Pd) solid solution with face-centered cubic structure when the Pd content is from 28.5 to 61.6 at% Pd, and the (-Fe, Pd) solid solution when the Pd content is from 69.5 at% to 77.1 at%.

Co-Pt alloy films were electrodeposited from a novel bath which was designed in the present study containing the ammonia solution and ammonium tartrate as complexing agents. The Co-Pt deposited films were prepared with wide alloy compositions ranging from 16.5 at% Pt to 56.8 at% Pt by changing the bath concentration and current density. The structures of these deposited films were analyzed by means of XRD and HRTEM. The results indicated that the crystallographic structure of Co-Pt deposited film are the "-Co solid solution when the platinum content in deposited film is below 31.1 at%, the mixture of "-Co solid solution and (-Co, Pt) face centered-cubic solid solution when the platinum in the deposited film is ranging from 35.7 at% to 45.7 at%, and the (-Co, Pt) face centered-cubic solid solution when the platinum in the deposited film is ranging from 51.1 at% to 56.8 at%. Moreover, the ordered fct phase (L1 0 ) was detected with the help of XRD from Co-Pt deposited film with 51.1 at% Pt which was annealed in vacuum with pressure no lower 10 À5 Pa for 60 min at the temperature of 450 C.